Premium
Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator?
Author(s) -
Orfanoudaki Eleni,
Drygiannakis Ioannis,
Koutroubakis Ioannis E.
Publication year - 2018
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.14980
Subject(s) - biosimilar , infliximab , medicine , innovator , inflammatory bowel disease , disease , gastroenterology , immunology , intellectual property , computer science , operating system
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom